RNACCartesian Therapeutics, Inc.

Sign up free
⚡

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire · Nov 5, 12:00 PM

Market reactionShares rose 11% on Nov 6.

IntactLast material event Aug 6, 2026 · Updated Oct 25, 2026

Cartesian's Phase 3 AURORA of Descartes-08 in myasthenia gravis reads out in Q1 2027, ahead of a planned mid-2027 BLA

Cartesian Therapeutics is a clinical-stage company developing Descartes-08, an mRNA CAR-T cell therapy for myasthenia gravis and other autoimmune diseases; it is not approved.

Cartesian's case rests on Descartes-08, an mRNA-based CAR-T therapy against BCMA given without chemotherapy pre-treatment, in myasthenia gravis, with deep Phase 2b responses through 12 months. The Phase 3 AURORA trial reports its primary endpoint in Q1 2027, and Cartesian plans a BLA in mid-2027. With $149.3 million in cash and a $150 million K2 HealthVentures credit facility, Cartesian expects runway into 2028.

Thesis checklist

0 risks need attention

Select a row for evidence
AURORA meets its primary endpointAwaiting evidenceNext: AURORA primary endpoint data (Q1 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Responses last and retreatment worksSupportedNext: Longer follow-up.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash and credit last into 2028SupportedNext: Q3 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

AURORA primary endpoint

Tests: AURORA meets its primary endpoint

Q1 2027

Does Descartes-08 improve myasthenia gravis symptoms versus placebo?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentCorporate
+4.9%Aug 6, 2026

Cartesian's Phase 3 AURORA of Descartes-08 in myasthenia gravis reads out in Q1 2027, ahead of a planned mid-2027 BLA

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Generalized myasthenia gravis
Descartes-08 · 2 upcoming · 1 completed
Phase 3 Data: ToplineAURORA
Q1 2027
BLA Submission
Mid 2027
Generalized myasthenia gravis· in vivo delivery
Descartes-08 · 1 upcoming
Phase 1 Study Initiation
2H 2026
Myositis· dermatomyositis and antisynthetase syndrome
Descartes-08 · 2 upcoming · 1 completed
Phase 2 Data: InterimTRITON
1H 2027
Phase 2 Data: ToplineTRITON
H1 2027
Juvenile dermatomyositis
Descartes-08 · 1 completed
Phase 1/2 Study InitiationHELIOS
Reported Apr 30, 2026
Systemic lupus erythematosus
Descartes-08 · 1 completed
Phase 2 Data: Interim
Reported Nov 13, 2025
Multiple myeloma
Descartes-15 · 1 completed
Phase 1 Data: Interim
Reported Nov 13, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Cartesian Therapeutics (RNAC) investment thesis intact?
Yes. Readouts currently rates the Cartesian Therapeutics Thesis Intact. Cartesian's Phase 3 AURORA of Descartes-08 in myasthenia gravis reads out in Q1 2027, ahead of a planned mid-2027 BLA.
What is the next catalyst for Cartesian Therapeutics (RNAC)?
The next dated event is Phase 1 start for Descartes-08, expected 2H 2026, as stated by the company. Also ahead: Phase 3 topline results (AURORA) for Descartes-08, expected Q1 2027.
How long will Cartesian Therapeutics' cash last?
Cartesian Therapeutics has said its cash will fund operations into 2028 (guidance as of November 5, 2026). It reported $125 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Disease areas: Blood cancers, Neuromuscular diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

11 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.